Skip to main navigation Skip to search Skip to main content

Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells

  • Gabriela Bottaro Gelaleti
  • , TF Borin
  • , LB Maschio-Signorini
  • , Marina Gobbe Moschetta
  • , Eva Hellmén
  • , AM Viloria Petit
  • , Debora Aparecida Pires de Campos Zuccari

    Publication: Contribution to journalJournal articlepeer-review

    Abstract

    Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cellsAim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures.Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array.Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments.Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
    Original languageEnglish
    Pages (from-to)1572-1584
    Number of pages13
    JournalVeterinary and Comparative Oncology
    Volume15
    Issue number4
    DOIs
    Publication statusPublished - 2017

    Keywords

    • angiogenesis
    • apoptosis
    • canine
    • interleukin-25
    • melatonin
    • mammary tumour cells

    Cite this